{
  "id": 19175636,
  "title": "Heron sells assets to CorMedix for $145M upfront; Faeth's stock tumbles",
  "url": "https://urgent.news/2026/11/09/heron-sells-assets-to-cormedix-for-145m-upfront-faeths-stock-tumbles",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T16:13:22.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/heron-sells-assets-to-cormedix-for-145m-upfront-faeths-stock-tumbles/"
  },
  "original_language": "en",
  "account": null,
  "summary": "CorMedix has acquired the Heron portfolio.\n\nFaeth Therapeutics announced data from its PIK-201 Phase 2 study of PIKTOR combined with paclitaxel. According to Investing.com, the study showed an objective response rate of 33% and a strong showing on progression-free survival. Baird noted that the trial demonstrated a differentiated safety profile with a low discontinuation rate and a low rate of Grade 3 or higher stomatitis.\n\nBaird stated that the results support the outlook for PIKTOR in endometrial cancer, with planning for Phase 3 currently underway. The firm also noted that the data should read through positively to breast cancer opportunities, with data expected in 2027. Baird reiterated an Outperform rating and a $57.00 price target for Faeth Therapeutics, noting that the current stock price of $12.21 represents substantial upside.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "CorMedix stock gains as Heron deal adds four products",
        "url": "https://urgent.news/2026/11/09/cormedix-stock-gains-as-heron-deal-adds-four-products",
        "published": "2026-11-09T13:29:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}